Desiree Gendron - Lexicon Pharmaceuticals Vice Training
| LXRX Stock | USD 0.86 0.09 11.69% |
Executive
Desiree Gendron is Vice Training of Lexicon Pharmaceuticals
| Address | 2445 Technology Forest Boulevard, The Woodlands, TX, United States, 77381 |
| Phone | 281 863 3000 |
| Web | https://www.lexpharma.com |
Lexicon Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4416) % which means that it has lost $0.4416 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3609) %, meaning that it created substantial loss on money invested by shareholders. Lexicon Pharmaceuticals' management efficiency ratios could be used to measure how well Lexicon Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.91 in 2024. Return On Capital Employed is likely to rise to -0.82 in 2024. At this time, Lexicon Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 104.9 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 786.6 K in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Mark Winderlich | Hookipa Pharma | 38 | |
| John Cavan | Hepion Pharmaceuticals | 66 | |
| Regan Lauer | Immunitybio | 54 | |
| Esq CPA | Ocean Biomedical | 59 | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| Lauren MBA | Day One Biopharmaceuticals | 48 | |
| Robert Felsch | Ardelyx | N/A | |
| Suba Krishnan | Mereo BioPharma Group | 59 | |
| Sarah Singleton | Immunitybio | N/A | |
| Kevin CPA | Enveric Biosciences | 60 | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Matthew Beck | Hookipa Pharma | N/A | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| MD MBA | Ocean Biomedical | 59 | |
| Scott Harris | Terns Pharmaceuticals | N/A | |
| Candice Masse | Elevation Oncology | N/A | |
| Robert Yang | Elevation Oncology | N/A | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| JD Esq | Terns Pharmaceuticals | 55 | |
Management Performance
| Return On Equity | -1.36 | ||||
| Return On Asset | -0.44 |
Lexicon Pharmaceuticals Leadership Team
Elected by the shareholders, the Lexicon Pharmaceuticals' board of directors comprises two types of representatives: Lexicon Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lexicon. The board's role is to monitor Lexicon Pharmaceuticals' management team and ensure that shareholders' interests are well served. Lexicon Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lexicon Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kenneth MD, Senior Assurance | ||
| Lonnel Coats, CEO and President and Director | ||
| Chas Schultz, Executive Advocacy | ||
| Robert MD, Consultant Director | ||
| Tom Garner, Senior Officer | ||
| Desiree Gendron, Vice Training | ||
| Jeffrey JD, President CFO | ||
| Mike Kelly, Investor Officer | ||
| Michael Exton, CEO Director | ||
| Thomas Garner, Senior Officer | ||
| Kristen Alexander, Vice Accounting | ||
| Dixon Terry, Vice Compliance | ||
| Carrie Siragusa, Vice Marketing | ||
| Alan Main, Executive VP of CMC and Supply Operations | ||
| Brian Crum, General VP | ||
| Wendy McDermott, Senior Resources | ||
| Lisa DeFrancesco, Corporate Relations |
Lexicon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lexicon Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.36 | ||||
| Return On Asset | -0.44 | ||||
| Operating Margin | (36.40) % | ||||
| Current Valuation | 154.94 M | ||||
| Shares Outstanding | 361.49 M | ||||
| Shares Owned By Insiders | 1.15 % | ||||
| Shares Owned By Institutions | 82.02 % | ||||
| Number Of Shares Shorted | 28.65 M | ||||
| Price To Earning | 21.02 X | ||||
| Price To Book | 1.75 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lexicon Stock Analysis
When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.